文献速递流行病学与生物统计真实世界研究与卫生经济

巴基斯坦信德省COVID-19疫苗接种的健康影响与成本效果建模研究

COVID-19 vaccination in Sindh Province, Pakistan: A modelling study of health impact and cost-effectiveness.
PubMed 文献 · PLoS Med · 2021-10-04

该建模研究将 compartmental 传播模型拟合至巴基斯坦信德省2020年4月30日至9月15日的COVID-19病例与死亡数据,并预测不同疫苗接种情景下10年内的健康与经济结局。优先接种65岁以上人群通常可避免更多死亡,但无优先分配在考虑所有结局时成本效果几乎相同。

要点

  • 在COVAX配送速率与低价疫苗条件下,接种可显著减少病例、死亡和DALY。
  • 优先接种65岁以上人群通常避免更多死亡,但在年轻人群中优势较小。
  • 高价疫苗(10美元/剂)可能不具成本效果,取决于疫苗性能与疫情趋势。

核心结论

  • COVID-19疫苗接种可产生显著健康影响,在较乐观的疫苗情景下可能具成本效果。
  • 预防重症是上述健康影响的重要贡献因素。
  • 在普遍较年轻的人群中,优先接种老年高风险人群的优势较小,若既往传播更多且疫苗能进一步阻断传播则尤为明显。

研究设计与样本

  • 将 compartmental 传播模型拟合至巴基斯坦信德省2020年4月30日至9月15日的COVID-19病例与死亡数据。
  • 预测不同疫苗情景下10年内的病例、死亡和住院结局,并结合经济模型估计增量成本、DALY和ICER。

主要发现

  • 按COVAX配送速率分发1年、使用单价3美元、有效性70%、保护期2.5年的感染阻断疫苗,可能避免约0.9百万病例(95% CrI: 0.9, 1.0)。
  • 同一情景可能避免10.1千死亡(95% CrI: 10.1, 10.3)和70.1千DALY(95% CrI: 69.9, 70.6)。
  • 从卫生系统角度,ICER为每避免1个DALY花费27.9美元。
  • 在广泛替代情景下,初始优先接种65岁以上人群通常预防更多死亡,但无优先分配在考虑所有结局时成本效果几乎相同。
  • 优先与无优先方案在低单价下均可具成本效果,而高价疫苗(10美元/剂)可能不具成本效果。

关键数值与推荐

  • 疫苗情景:单价3美元/剂、有效性70%、保护期2.5年、感染阻断疫苗、配送速率与COVAX预测一致。
  • 健康结局:避免约0.9百万病例、10.1千死亡、70.1千DALY(95% CrI分别为0.9–1.0、10.1–10.3、69.9–70.6)。
  • 成本效果:卫生系统角度ICER为27.9美元/DALY避免。
  • 高价疫苗(10美元/剂)可能不具成本效果,取决于疫苗性能、配送方案和未来疫情趋势。

临床怎么用

  • 在低收入和中等收入国家背景下,低价疫苗大规模接种可能具成本效果。
  • 初始优先接种65岁以上人群通常可预防更多死亡,但需结合人群年龄结构与既往传播水平权衡。
  • 疫苗定价显著影响成本效果,高价可能限制其可推广性。

局限性

  • 模型为单人群 compartmental 模型,无法实际表示或评估非药物干预(NPI)的详细影响及其与疫苗规划的联合作用。
  • 模型无法考虑优先接种医护人员或其他必要工作者等群体。
  • 模型仅拟合报告的病例和死亡数据,数据不完整且未按年龄等分层。
  • 未来NPI的影响和实施成本不确定,其与疫苗接种的交互作用仍是未解问题。
  • 研究受模型近似、可用数据和未来不确定性限制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Multiple Coronavirus Disease 2019 (COVID-19) vaccines appear to be safe and efficacious, but only high-income countries have the resources to procure sufficient vaccine doses for most of their eligible populations. The World Health Organization has published guidelines for vaccine prioritisation, but most vaccine impact projections have focused on high-income countries, and few incorporate economic considerations. To address this evidence gap, we projected the health and economic impact of different vaccination scenarios in Sindh Province, Pakistan (population: 48 million). METHODS AND FINDINGS: We fitted a compartmental transmission model to COVID-19 cases and deaths in Sindh from 30 April to 15 September 2020. We then projected cases, deaths, and hospitalisation outcomes over 10 years under different vaccine scenarios. Finally, we combined these projections with a detailed economic model to estimate incremental costs (from healthcare and partial societal perspectives), disability-adjusted life years (DALYs), and incremental cost-effectiveness ratio (ICER) for each scenario. We project that 1 year of vaccine distribution, at delivery rates consistent with COVAX projections, using an infection-blocking vaccine at $3/dose with 70% efficacy and 2.5-year duration of protection is likely to avert around 0.9 (95% credible interval (CrI): 0.9, 1.0) million cases, 10.1 (95% CrI: 10.1, 10.3) thousand deaths, and 70.1 (95% CrI: 69.9, 70.6) thousand DALYs, with an ICER of $27.9 per DALY averted from the health system perspective. Under a broad range of alternative scenarios, we find that initially prioritising the older (65+) population generally prevents more deaths. However, unprioritised distribution has almost the same cost-effectiveness when considering all outcomes, and both prioritised and unprioritised programmes can be cost-effective for low per-dose costs. High vaccine prices ($10/dose), however, may not be cost-effective, depending on the specifics of vaccine performance, distribution programme, and future pandemic trends. The principal drivers of the health outcomes are the fitted values for the overall transmission scaling parameter and disease natural history parameters from other studies, particularly age-specific probabilities of infection and symptomatic disease, as well as social contact rates. Other parameters are investigated in sensitivity analyses. This study is limited by model approximations, available data, and future uncertainty. Because the model is a single-population compartmental model, detailed impacts of nonpharmaceutical interventions (NPIs) such as household isolation cannot be practically represented or evaluated in combination with vaccine programmes. Similarly, the model cannot consider prioritising groups like healthcare or other essential workers. The model is only fitted to the reported case and death data, which are incomplete and not disaggregated by, e.g., age. Finally, because the future impact and implementation cost of NPIs are uncertain, how these would interact with vaccination remains an open question. CONCLUSIONS: COVID-19 vaccination can have a considerable health impact and is likely to be cost-effective if more optimistic vaccine scenarios apply. Preventing severe disease is an important contributor to this impact. However, the advantage of prioritising older, high-risk populations is smaller in generally younger populations. This reduction is especially true in populations with more past transmission, and if the vaccine is likely to further impede transmission rather than just disease. Those conditions are typical of many low- and middle-income countries.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Pearson CAB, Bozzani F, Procter SR, et al. COVID-19 vaccination in Sindh Province, Pakistan: A modelling study of health impact and cost-effectiveness. PLoS Med. 2021. PMID: 34606520. doi:10.1371/journal.pmed.1003815

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。